RU2351590C2 - Способ получения диариламина - Google Patents

Способ получения диариламина Download PDF

Info

Publication number
RU2351590C2
RU2351590C2 RU2005128274/04A RU2005128274A RU2351590C2 RU 2351590 C2 RU2351590 C2 RU 2351590C2 RU 2005128274/04 A RU2005128274/04 A RU 2005128274/04A RU 2005128274 A RU2005128274 A RU 2005128274A RU 2351590 C2 RU2351590 C2 RU 2351590C2
Authority
RU
Russia
Prior art keywords
formula
compound
alkali metal
group
metal salt
Prior art date
Application number
RU2005128274/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2005128274A (ru
Inventor
Джон Р. СНУНИАН (US)
Джон Р. СНУНИАН
Патрика-Энн ОЛИВЕР-ШЕФФЕР (US)
Патрика-Энн ОЛИВЕР-ШЕФФЕР
Original Assignee
Вертекс Фармасьютикалз Инкорпорейтед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Вертекс Фармасьютикалз Инкорпорейтед filed Critical Вертекс Фармасьютикалз Инкорпорейтед
Publication of RU2005128274A publication Critical patent/RU2005128274A/ru
Application granted granted Critical
Publication of RU2351590C2 publication Critical patent/RU2351590C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/803—Processes of preparation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2005128274/04A 2003-02-10 2004-02-10 Способ получения диариламина RU2351590C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US44664103P 2003-02-10 2003-02-10
US60/446,641 2003-02-10
US47427203P 2003-05-28 2003-05-28
US60/474,272 2003-05-28

Publications (2)

Publication Number Publication Date
RU2005128274A RU2005128274A (ru) 2006-01-27
RU2351590C2 true RU2351590C2 (ru) 2009-04-10

Family

ID=32871996

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005128274/04A RU2351590C2 (ru) 2003-02-10 2004-02-10 Способ получения диариламина

Country Status (12)

Country Link
US (3) US7115746B2 (enExample)
EP (2) EP2562158A1 (enExample)
JP (4) JP4675318B2 (enExample)
KR (1) KR20050101200A (enExample)
CN (1) CN101723891A (enExample)
AU (1) AU2004212494B2 (enExample)
CA (2) CA2755297A1 (enExample)
MX (1) MXPA05008450A (enExample)
NO (1) NO20054201L (enExample)
NZ (1) NZ542153A (enExample)
RU (1) RU2351590C2 (enExample)
WO (1) WO2004072038A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2510393C2 (ru) * 2009-02-27 2014-03-27 Тейдзин Фарма Лимитед Способ получения фенилзамещенного гетероциклического производного посредством сочетания с использованием переходного металла в качестве катализатора
RU2537848C1 (ru) * 2013-12-10 2015-01-10 Федеральное государственное казенное учреждение "33 Центральный научно-исследовательский испытательный институт Министерства обороны Российской Федерации" Способ получения 2-хлор-5-гидроксиметилпиридина
RU2563459C2 (ru) * 2010-08-27 2015-09-20 Тейдзин Фарма Лимитед Способ получения фенилзамещенного гетероциклического производного посредством способа сочетания с использованием соединения палладия

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4675318B2 (ja) * 2003-02-10 2011-04-20 バーテックス ファーマシューティカルズ インコーポレイテッド Ｎ−アリールカルバミン酸エステルとハロ−ヘテロアリールとを反応させることによるｎ−ヘテロアリール−ｎ−アリール−アミンの調製のためのプロセスおよび類似のプロセス
ATE352550T1 (de) 2003-09-19 2007-02-15 Astrazeneca Ab Chinazolinderivate
BRPI0608910A2 (pt) * 2005-05-09 2010-02-17 Achillion Pharmaceuticals Inc uso de um composto da fórmula ou um sal ou hidrato farmaceuticamente aceitável desse, composto ou sal ou hidrato do mesmo, composição farmacêutica e composição farmacêutica embalada
JP2008545696A (ja) * 2005-05-23 2008-12-18 スミスクライン・ビーチャム・コーポレイション 肥満の処置のためのｐ３８ｍａｒｋの阻害
SI1945632T1 (sl) 2005-11-08 2014-03-31 Vertex Pharmaceuticals Incorporated Heterocikliäśni modulatorji za prenaĺ alce z atp-vezavno kaseto
MX2008011490A (es) * 2006-03-07 2009-01-07 Vertex Pharma Composiciones y metodos para tratar artritis reumatoide.
AU2007223797A1 (en) * 2006-03-08 2007-09-13 Achillion Pharmaceuticals, Inc. Substituted aminothiazole derivatives with anti-HCV activity
NZ581259A (en) 2007-05-09 2012-07-27 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
BRPI0811939A2 (pt) * 2007-05-22 2014-11-25 Achillion Pharmaceuticals Inc Tiazóis substituídos por heteroarila
SI2209778T1 (sl) 2007-09-21 2012-12-31 Array Biopharma, Inc. Piridin-2-il-amino-I, 2,4-tiadiazol derivati kot aktivatorji glukokinaze za zdravljenje sladkorne bolezni
AU2008333845C1 (en) 2007-12-07 2014-01-16 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
AU2013205160B2 (en) * 2007-12-07 2016-05-19 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
SI2639224T1 (sl) 2007-12-07 2016-12-30 Vertex Pharmaceuticals Incorporated Postopek za pripravo cikloalkilkarboksiamido-piridinskih benzojskih kislin
CN102245573B (zh) 2008-02-28 2013-11-20 沃泰克斯药物股份有限公司 作为cftr调节剂的杂芳基衍生物
CN104262267B9 (zh) * 2008-03-18 2019-04-12 艾尼纳制药公司 用于治疗前列环素(pgi2)受体相关病症的pgi2受体调节剂
US8106209B2 (en) * 2008-06-06 2012-01-31 Achillion Pharmaceuticals, Inc. Substituted aminothiazole prodrugs of compounds with anti-HCV activity
US20110224262A1 (en) 2008-11-26 2011-09-15 Arena Pharmaceuticals, Inc. Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
PL2370413T3 (pl) 2008-12-08 2016-01-29 Arena Pharm Inc Modulatory receptora prostacykliny (PGI2) użyteczne w leczeniu zaburzeń z nimi związanych
EP2396302A2 (en) 2009-02-13 2011-12-21 Vertex Pharmceuticals Incorporated Processes for producing phenyl-6-(1-(phenyl)ureido)nicotinamides)
CN102378756A (zh) 2009-02-13 2012-03-14 沃泰克斯药物股份有限公司 2-(2,4-二氟苯基)-6-(1-(2,6-二氟苯基)脲基)烟酰胺的固体形式
GB0908317D0 (en) * 2009-05-14 2009-06-24 Argenta Discovery Ltd Pharmaceutical compounds and compositions
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
LT3150198T (lt) 2010-04-07 2021-12-10 Vertex Pharmaceuticals Incorporated 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties farmacinė kompozicija ir jos įvedimas
DE102012003281B4 (de) 2011-02-24 2014-02-13 Tokai Rubber Industries, Ltd. Berührungsschalter
BR112016010403A2 (pt) 2013-11-12 2017-08-08 Vertex Pharma Processo de preparação de composições farmacêuticas para o tratamento de doenças mediadas por cftr
EA201790905A1 (ru) 2014-10-23 2017-09-29 Арена Фармасьютикалз, Инк. Способ лечения состояний, связанных с рецептором pgi2
CA2968130C (en) 2014-11-18 2022-08-16 Vertex Pharmaceuticals Incorporated Process of conducting high throughput testing high performance liquid chromatography
KR20230021186A (ko) 2016-11-10 2023-02-13 아레나 파마슈티칼스, 인크. 라리네팍 및 다른 제제의 조합에 의한 pah의 치료 방법
CN110582271B (zh) 2017-03-01 2022-06-14 阿瑞那制药公司 包含pgi2受体激动剂的组合物及其制备方法
CA3127373A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
EP3796902A1 (en) 2018-05-16 2021-03-31 Arena Pharmaceuticals, Inc. Compositions comprising pgi2-receptor agonists and processes for the preparation thereof
TW202112368A (zh) 2019-06-13 2021-04-01 荷蘭商法西歐知識產權股份有限公司 用於治療有關dux4表現之疾病的抑制劑組合
WO2022175752A1 (en) 2021-02-19 2022-08-25 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
AU2022222470A1 (en) 2021-02-19 2023-09-21 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
WO2023158634A1 (en) 2022-02-15 2023-08-24 United Therapeutics Corporation Crystalline prostacyclin (ip) receptor agonist and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU517247A3 (ru) * 1971-04-07 1976-06-05 Империал Кемикал Индастриз Лимитед (Фирма) Способ очистки диариламинов

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ302117A (en) 1995-01-12 1999-10-28 Smithkline Beecham Corp 1-cycloalkyl or cycloalkylalkyl 4,5-trisubstituted imidazole derivatives and medicaments
MY132496A (en) 1998-05-11 2007-10-31 Vertex Pharma Inhibitors of p38
AU762245B2 (en) 1998-09-18 2003-06-19 Vertex Pharmaceuticals Incorporated Inhibitors of p38
AU8323701A (en) * 2000-08-11 2002-02-25 John Cochran Inhibitors of p38
WO2003000189A2 (en) * 2001-06-21 2003-01-03 Baylor College Of Medicine Prediction, diagnosis and treatment of endocrine resistant breast cancer, using p38 mapk pathway
JP4675318B2 (ja) * 2003-02-10 2011-04-20 バーテックス ファーマシューティカルズ インコーポレイテッド Ｎ−アリールカルバミン酸エステルとハロ−ヘテロアリールとを反応させることによるｎ−ヘテロアリール−ｎ−アリール−アミンの調製のためのプロセスおよび類似のプロセス

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU517247A3 (ru) * 1971-04-07 1976-06-05 Империал Кемикал Индастриз Лимитед (Фирма) Способ очистки диариламинов

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. Cao et al, Bioorg. Med. Chem. Lett., vol.11 no.24 (2001), 3169-3173. Murakami et al, Chem. Pharm. Bull., vol.43, no.8 (1995), 1287-1293. *
SUCHOLEIKI ET AL, TETRAHEDRON LETTERS, vol.42, no.19 (2001), 3279-3282. SETO ETAL, J. MED. CHEM., vol.115, no.4 (1993), 1321-1329. REWCASTLE ET AL., vol.30, no.9, 1576-1581. *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2510393C2 (ru) * 2009-02-27 2014-03-27 Тейдзин Фарма Лимитед Способ получения фенилзамещенного гетероциклического производного посредством сочетания с использованием переходного металла в качестве катализатора
RU2510393C9 (ru) * 2009-02-27 2014-08-27 Тейдзин Фарма Лимитед Способ получения фенилзамещенного гетероциклического производного посредством сочетания с использованием переходного металла в качестве катализатора
RU2563459C2 (ru) * 2010-08-27 2015-09-20 Тейдзин Фарма Лимитед Способ получения фенилзамещенного гетероциклического производного посредством способа сочетания с использованием соединения палладия
RU2537848C1 (ru) * 2013-12-10 2015-01-10 Федеральное государственное казенное учреждение "33 Центральный научно-исследовательский испытательный институт Министерства обороны Российской Федерации" Способ получения 2-хлор-5-гидроксиметилпиридина

Also Published As

Publication number Publication date
US7115746B2 (en) 2006-10-03
US8686157B2 (en) 2014-04-01
AU2004212494B2 (en) 2011-03-17
CA2755297A1 (en) 2004-08-26
EP1603878B1 (en) 2013-01-02
US20120157684A1 (en) 2012-06-21
NO20054201D0 (no) 2005-09-09
CA2515669A1 (en) 2004-08-26
JP2014133745A (ja) 2014-07-24
JP4675318B2 (ja) 2011-04-20
RU2005128274A (ru) 2006-01-27
EP2562158A1 (en) 2013-02-27
NZ542153A (en) 2009-01-31
HK1087117A1 (zh) 2006-10-06
KR20050101200A (ko) 2005-10-20
JP2011037909A (ja) 2011-02-24
US20040230058A1 (en) 2004-11-18
US20070173649A1 (en) 2007-07-26
CN101723891A (zh) 2010-06-09
MXPA05008450A (es) 2005-10-18
JP2006517235A (ja) 2006-07-20
NO20054201L (no) 2005-10-06
WO2004072038A1 (en) 2004-08-26
JP2011037908A (ja) 2011-02-24
EP1603878A1 (en) 2005-12-14
US8034950B2 (en) 2011-10-11
AU2004212494A1 (en) 2004-08-26

Similar Documents

Publication Publication Date Title
RU2351590C2 (ru) Способ получения диариламина
JP2006517235A5 (enExample)
PL195808B1 (pl) Moczniki arylowe, kompozycja je zawierająca i ichzastosowanie
JP5693239B2 (ja) ４−ピリジノン化合物および癌についてのその使用
CN111295381A (zh) 可用于合成抗蛋白激酶的选择性抑制剂的中间体及其制备方法
JP6513105B2 (ja) トリアジン、ピリミジン及びピリジン誘導体の新規製造方法
CN100579965C (zh) 通过使n-芳基氨基甲酸酯与卤代杂芳基反应制备n-杂芳基-n-芳基胺的方法和类似方法
TW202239409A (zh) 化合物
US8273896B2 (en) Processes for producing phenyl-6-(1-(phenyl)ureido)nicotinamides
HK1144936A (en) Processes for the preparation of n-heteroaryl-n-aryl-amines by reacting an n-aryl carbamic acid ester with a halo-heteroaryl and analogous processes
HK1087117B (en) Processes for the preparation of n-heteroaryl-n-aryl-amines by reacting an n-aryl carbamic acid ester with a halo-heteroaryl and analogous processes
CN103209961A (zh) 用于制备2,3-二氨基丙酸衍生物的对映异构体形式的方法
JP2001515065A (ja) 置換２−ニトログアニジン誘導体の製造方法
CN104379564A (zh) 通过2,2-二氟乙胺的烷基化制备2,2-二氟乙胺衍生物的方法
HK1163091A (en) Processes for producing phenyl-6-(1-(phenyl)ureido)nicotinamides)

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20130211